Advertisement

Occult Malignancy Rate of 1498 Hysterectomies or Myomectomies with Morcellation: A Retrospective Single-Arm Study

  • Garri Tchartchian
  • Bernd Bojahr
  • Sven Becker
  • Attilio Di Spiezio Sardo
  • Vasilis Tanos
  • Hugo C. Verhoeven
  • Markus Wallwiener
  • Rudy L. De Wilde
Original Article
  • 3 Downloads

Abstract

Background and Purpose

Since April 2014, the FDA warns against the use of morcellation during minimally invasive uterine surgery because of the risk of occult malignant spreading in the abdominal cavity. It is clear, however, that more studies are needed to define the incidence of occult uterine cancers, its risk factors, preoperative identification and postoperative follow-up. The present retrospective single-arm study defines the prevalence of occult uterine malignancies in a large group of patients treated with hysterectomy or myomectomy for benign indications.

Methods

In the year of 2014, 1498 women admitted for a myomectomy or hysterectomy in benign conditions at the clinic of minimally invasive surgery (Minimal Invasive Chirurgie or MIC) in Berlin (Germany) were included in this study. The morcellated uterine specimens of operated patients were histologically analyzed for the presence of cancerous tissue.

Results

We detected malignancies in three of the 1498 women (0.2%): two patients had endometrial cancer, while we observed cervical cancer in situ in the third patient. No sarcoma was found.

Conclusion

We detected a very low prevalence of occult uterine malignancy which is in line with several other recent studies. To define a clear policy on the use of morcellation, more studies are required. In the meantime, patients should be informed about the risks of morcellation in case of undetected cancer prior to surgery.

Keywords

Morcellation Laparoscopy Hysterectomy Myomectomy Malignancy 

Notes

Compliance with Ethical Standards

Conflict of interest

Garri Tchartchian, Bernd Bojahr, Sven Becker, Attilio Di Spiezio Sardo, Vasilis Tanos, Hugo Christian Verhoeven, Markus Wallwiener, Rudy L De Wilde declare that they have no conflict of interest.

Ethical Approval

For the present retrospective study, no ethical approval is required in Germany. Prof. Dr. Rudy L De Wilde, head of the University Clinic of Gynecology in Oldenburg, Germany, approved and supervised the present study from conception through manuscript submission.

Informed Consent

Retrospectively, we selected our patient group based on matching inclusion and exclusion criteria, and we contacted each of those patients to obtain informed consent before the inclusion of their data in this study.

References

  1. 1.
    Muller A, Thiel FC, Renner SP, et al. Hysterectomy-a comparison of approaches. Dtsch Arzteblatt Int. 2010;107(20):353–9.Google Scholar
  2. 2.
    Hammer A, Rositch AF, Kahlert J, et al. Global epidemiology of hysterectomy: possible impact on gynecological cancer rates. Am J Obstet Gynecol. 2015;213(1):23–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Donnez O, Jadoul P, Squifflet J, et al. A series of 3190 laparoscopic hysterectomies for benign disease from 1990 to 2006: evaluation of complications compared with vaginal and abdominal procedures. BJOG. 2009;116(4):492–500.CrossRefPubMedGoogle Scholar
  4. 4.
    Mourits MJ, Bijen CB, Arts HJ, et al. Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial. Lancet Oncol. 2010;11(8):763–71.CrossRefGoogle Scholar
  5. 5.
    Brill AI. Hysterectomy in the 21st century: different approaches, different challenges. Clin Obstet Gynecol. 2006;49(4):722–35.CrossRefPubMedGoogle Scholar
  6. 6.
    Morelli M, Caruso M, Noia R, et al. Total laparoscopic hysterectomy versus vaginal hysterectomy: a prospective randomized trial. Minerva Ginecol. 2007;59(2):99–105.PubMedGoogle Scholar
  7. 7.
    US FDA. UPDATED laparoscopic uterine power morcellation in hysterectomy and myomectomy: FDA safety communication. 2014. http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm424443.htm. Accessed 16 Oct 2015.
  8. 8.
    AAGL. Morcellation during uterine tissue extraction. 2014. http://www.aagl.org/wp-content/uploads/2014/05/Tissue_Extraction_TFR.pdf. Accessed 16 Oct 2015.
  9. 9.
    Bethesda M. SEER cancer statistics factsheets: endometrial cancer. National Cancer Institute. 2014. http://seer.cancer.gov/statfacts/html/corp.html. Accessed 16 Oct 2015.
  10. 10.
    Bojahr B, Raatz D, Schonleber G, et al. Perioperative complication rate in 1706 patients after a standardized laparoscopic supracervical hysterectomy technique. J Minim Invasive Gynecol. 2006;13(3):183–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Bojahr B, Tchartchian G, Ohlinger R. Laparoscopic supracervical hysterectomy: a retrospective analysis of 1000 cases. JSLS. 2009;13(2):129–34.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Tchartchian G, Gardanis K, Bojahr B, et al. Postoperative patient satisfaction after laparoscopic supracervical hysterectomy. JSLS. 2013;17(1):107–10.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Hackethal A, Westermann A, Tchartchian G, et al. Laparoscopic myomectomy in patients with uterine myomas associated with infertility. MITA. 2011;20(6):338–45.Google Scholar
  14. 14.
    Agdi M, Tulandi T. Endoscopic management of uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2008;22(4):707–16.CrossRefPubMedGoogle Scholar
  15. 15.
    Ciszak T, Mittal PK, Sullivan P, et al. Case report: MR imaging features of disseminated uterine leiomyosarcoma presenting after hysterectomy with morcellation. Abdom Imaging. 2015;40(7):2600–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Hill AJ, Carroll AW, Matthews CA. Unanticipated uterine pathologic finding after morcellation during robotic-assisted supracervical hysterectomy and cervicosacropexy for uterine prolapse. Female Pelvic Med Reconstr Surg. 2014;20(2):113–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Turner T, Secord AA, Lowery WJ, et al. Metastatic adenocarcinoma after laparoscopic supracervical hysterectomy with morcellation: a case report. Gynecol Oncol Case Rep. 2013;5:19–21.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Della Badia C, Karini H. Endometrial stromal sarcoma diagnosed after uterine morcellation in laparoscopic supracervical hysterectomy. J Minim Invasive Gynecol. 2010;17(6):791–3.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Choo KJ, Lee HJ, Lee TS, et al. Intrapelvic dissemination of early low-grade endometrioid stromal sarcoma due to electronic morcellation. Obstet Gynecol Sci. 2015;58(5):414–7.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Hagemann IS, Hagemann AR, LiVolsi VA, et al. Risk of occult malignancy in morcellated hysterectomy: a case series. Int J Gynecol Pathol. 2011;30(5):476–83.CrossRefPubMedGoogle Scholar
  21. 21.
    Mowers EL, Skinner B, McLean K, et al. Effects of morcellation of uterine smooth muscle tumor of uncertain malignant potential and endometrial stromal sarcoma: case series and recommendations for clinical practice. J Minim Invasive Gynecol. 2015;22(4):601–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Einstein MH, Barakat RR, Chi DS, et al. Management of uterine malignancy found incidentally after supracervical hysterectomy or uterine morcellation for presumed benign disease. Int J Gynecol Cancer. 2008;18(5):1065–70.CrossRefPubMedGoogle Scholar
  23. 23.
    Administration USFaD. Laparoscopic uterine power morcellation in hysterectomy and myomectomy: FDA safety communication. 2014. https://www.chartrrg.com/wpcontent/uploads/2014/07/FDA-Warning.pdf. Accessed 12 Nov 2015.
  24. 24.
    Harris JA, Swenson CW, Uppal S, et al. Practice patterns and postoperative complications before and after food and drug administration safety communication on power morcellation. Am J Obstet Gynecol. 2016;214(1):98.e1–13.CrossRefGoogle Scholar
  25. 25.
    Lieng M, Berner E, Busund B. Risk of morcellation of uterine leiomyosarcomas in laparoscopic supracervical hysterectomy and laparoscopic myomectomy, a retrospective trial including 4791 women. J Minim Invasive Gynecol. 2015;22(3):410–4.CrossRefPubMedGoogle Scholar
  26. 26.
    Graebe K, Garcia-Soto A, Aziz M, et al. Incidental power morcellation of malignancy: a retrospective cohort study. Gynecol Oncol. 2015;136(2):274–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Brown J, Taylor K, Ramirez PT, et al. Laparoscopic supracervical hysterectomy with morcellation: should it stay or should it go? J Minim Invasive Gynecol. 2015;22(2):185–92.CrossRefPubMedGoogle Scholar
  28. 28.
    Tan A, Salfinger S, Tan J, et al. Morcellation of occult uterine malignancies: an Australian single institution retrospective study. Aust N Z J Obstet Gynaecol. 2015;55(5):503–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Bojahr B, De Wilde RL, Tchartchian G. Malignancy rate of 10,731 uteri morcellated during laparoscopic supracervical hysterectomy (LASH). Arch Gynecol Obstet. 2015;292(3):665–72.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Wright JD, Cui RR, Wang A, et al. Economic and survival implications of use of electric power morcellation for hysterectomy for presumed benign gynecologic disease. J Natl Cancer Inst. 2015.  https://doi.org/10.1093/jnci/djv251.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Singh SS, Scott S, Bougie O, et al. Technical update on tissue morcellation during gynaecologic surgery: its uses, complications, and risks of unsuspected malignancy. JOGC. 2015;37(1):68–81.PubMedGoogle Scholar
  32. 32.
    Rimbach S, Holzknecht A, Nemes C, et al. A new in-bag system to reduce the risk of tissue morcellation: development and experimental evaluation during laparoscopic hysterectomy. Arch Gynecol Obstet. 2015;292(6):1311–20.CrossRefPubMedGoogle Scholar
  33. 33.
    Rivard C, Salhadar A, Kenton K. New challenges in detecting, grading, and staging endometrial cancer after uterine morcellation. J Minim Invasive Gynecol. 2012;19(3):313–6.CrossRefPubMedGoogle Scholar
  34. 34.
    George S, Barysauskas C, Serrano C, et al. Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma. Cancer. 2014;120(20):3154–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Park JY, Kim DY, Kim JH, et al. The impact of tumor morcellation during surgery on the outcomes of patients with apparently early low-grade endometrial stromal sarcoma of the uterus. Ann Surg Oncol. 2011;18(12):3453–61.CrossRefPubMedGoogle Scholar
  36. 36.
    Picerno TM, Wasson MN, Gonzalez Rios AR, et al. Morcellation and the incidence of occult uterine malignancy: a dual-institution review. Int J Gynecol Cancer. 2016;26(1):149–55.CrossRefPubMedGoogle Scholar
  37. 37.
    Pritts EA, Parker WH, Brown J, et al. Outcome of occult uterine leiomyosarcoma after surgery for presumed uterine fibroids: a systematic review. J Minim Invasive Gynecol. 2015;22(1):26–33.CrossRefPubMedGoogle Scholar

Copyright information

© Federation of Obstetric & Gynecological Societies of India 2018

Authors and Affiliations

  1. 1.Klinik für Minimal Invasive ChirurgieBerlin-ZehlendorfGermany
  2. 2.Klinik für Gynäkologie und GeburtshilfeUniversitätsklinikum FrankfurtFrankfurt am MainGermany
  3. 3.Università degli Studi di Napoli Federico IINaplesItaly
  4. 4.Aretaeio Hospital and St Georges Medical SchoolNicosia UniversityNicosiaCyprus
  5. 5.Private Medical Center for Endocrinology, Gynecology, Reproductive Medicine and Preventive MedicineDüsseldorfGermany
  6. 6.Zentrum Gynäkologische Krebserkrankungen MIC II, Allgemeine Frauenheilkunde und GeburtshilfeUniversitätsklinikum HeidelbergHeidelbergGermany
  7. 7.Klinik für Frauenheilkunde, Geburtshilfe und Gynäkologische OnkologieUniversitätsklinik für Gynäkologie, Pius-Hospital OldenburgOldenburgGermany

Personalised recommendations